Transcode Therapeutics Inc - ESG Rating & Company Profile powered by AI
The webpage contains a zero-cost Sustainability assessment covering Transcode Therapeutics Inc. Detailed ESG analysis of Transcode Therapeutics Inc can be accessed by signing up for free. The assessment of Transcode Therapeutics Inc is assembled by All Street Sevva using leading NLP.
Transcode Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Transcode Therapeutics Inc | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Transcode Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Transcode Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Transcode Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Transcode Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Transcode Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Transcode Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Transcode Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Transcode Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Transcode Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Transcode Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Transcode Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Transcode Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Transcode Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Transcode Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Transcode Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Transcode Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Transcode Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Transcode Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA"based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9"based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.